ABSTRACT Lymphocytes from lymph nodes obtained at mastectomy in breast cancer patients have been fused with murine nonproducer myeloma cells to obtain human-mouse hybridoma cultures that synthesize human monoclonal antibodies. To Several investigators have presented evidence for the existence of antigens associated with human mammary tumors (1) (2) (3) (4) (5) (6) (7) (8) . The studies reported here were undertaken with the hypothesis that B lymphocytes in the axillary lymph nodes of patients with primary breast tumors or in lymph nodes containing metastatic mammary carcinoma cells may already be primed to synthesize antibodies against antigens shed by tumor cells Previous studies have demonstrated that human lymphocyte cells can be fused with murine cells, resulting in cultures that secrete human Igs (9) (10) (11) . It appeared logical, therefore, to exploit the now classical hybridoma technique (12) to produce human-mouse hybridoma cultures in an attempt to generate monoclonal antibodies reactive with antigens of mammary carcinoma cells. Human lymphocytes, obtained from segments of lymph nodes removed at mastectomy, were fused with nonproducer murine NS-1 myeloma cells (13) to obtain hybridoma cultures. (16) . After being rinsed in Pi/NaCl, the slides were incubated with a 1:5 dilution of normal goat serum for 15 min.
MATERIALS AND METHODS
This serum was removed and human monoclonal antibody (0.5-1.6 gg in 0.1 ml) or polyclonal human IgM (used at an identical Ig concentration as a negative control) was added for 30 min. The slides were then rinsed in Pi/NaCl and incubated with a 1:1000 dilution of horseradish peroxidase-conjugated goat anti-human IgG ('y chain-specific) or anti-human IgM (,u chain-specific) for 30 min; this dilution was nonreactive with endogenous membrane-bound Ig. The sections were then rinsed in Pi/NaCl, treated with 0.06% diaminobenzidine and 0.01% H202 for 5 min, and rinsed in Pi/NaCl; They were then counterstained with hematoxylin, dehydrated, and mounted (16 (Fig. 1) . Similarly, rabbit antiserum prepared against murine K chains also failed to react with these hybridoma supernatant fluids. A solid-phase linker radioimmunoassay that could detect 30 ng of murine Ig also failed to detect any murine Ig in human monoclonal antibody supernatant fluids.
Several of the human-mouse hybridoma supernatant fluids were analyzed by NaDodSO4/polyacrylamide gel electrophoresis and found to possess complete Ig (i.e., both heavy and light chains). For (Fig. 2A) Fig. 2A) and "nonmalignant" mammary epithelium or stromal cells (Fig.  2B) of the same breast Occasionally, a diffuse staining of stroma was observed; this staining appeared to be nonspecific because it was also observed with normal human IgM (polyclonal) preparations.
Antibody MBE6 was then tested for its ability to detect metastatic mammary carcinoma cells in the lymph nodes of patient MB (13 of 16 lymph nodes were histologically positive for tumor). MBE6 could clearly distinguish between metastatic breast cells and lymphocytes (Fig. 2C) . Variation in intensity of staining was also observed within a given population of metastatic cells of a given lymph node; tumor cells were detected by the immunoperoxidase technique, however, in 13 of 16 nodes of patient MB.
Antibody MBE6 was also tested for its ability to bind to mammary carcinoma cells of patients other than MB. Fig. 2D and Monoclonal antibody MBE6 was also tested for its ability to detect metastatic mammary carcinoma cells in lymph nodes of patients other than MB. As exemplified in Fig. 2F and Table  3 , MBE6 could readily discriminate between mammary carcinoma cells and adjacent lymphocytes or stroma in metastatic lymph nodes of breast cancer patients.
Differences in intensity and pattern of staining were observed in various areas of a given mammary tumor. Some tumor cells demonstrated intense staining throughout the cytoplasm; such heavily stained cells were often immediately adjacent to unstained tumor cells (Fig. 2G) . Alternatively, some tumor cells showed a more localized perinuclear stain (Fig. 2H, arrow) . To date, monoclonal MBE6 has demonstrated reactions with mammary carcinoma cells of 55 of 59 patients tested.
DISCUSSION
These studies demonstrate that stable clones of human-mouse hybridomas that secrete complete human Ig can be established from human lymph nodes. To date, more than 50 hybridoma cultures, secreting either human IgG or IgM, have been obtained from lymph nodes of 13 mastectomy patients. One point that should be stressed in obtaining stable human-mouse hybridoma clones is the planting of numerous cloning wells. With more wells planted, the probability of obtaining at least one stable clone is greater. These studies were undertaken with the hypothesis that B lymphocytes, obtained from segments of lymph nodes that are draining primary breast tumors or themselves containing metastatic breast tumor cells, may already be primed to antigens being shed by tumor cells. The immunoperoxidase results obtained to date support this hypothesis. It must be pointed out, however, that no lymph nodes from normal-i.e., donors other than mastectomy patientshave been analyzed to date. It will be of interest to define the variables (such as age of patient, pathologic description of tumor, or degree of lymph node metastasis) that influence whether a given fusion will result in the successful generation of hybridomas synthesizing human Igs.
The nature of immunologic reactivity of the human monoclonal antibody MBE6 requires further definition. As described in the text, a small population of "normal" mammary epithelial cells, adjacent to breast tumor cells of some patients, and a few of the benign breast tumors tested did stain in the immunoperoxidase reaction. One of several possible explanations is that these cells may represent a dedifferentiated or premalignant population. Furthermore, selected other malignant tissues (such as medullary thyroid carcinoma and bronchial alveolar carcinoma) also demonstrated some degree of staining. The staining of these other tissues was more diffuse than the intense staining observed with the majority of malignant mammary carcinoma cells. With the immunoperoxidase technique, however, it is not 
